Biostar Pharmaceuticals Stock Price To Earning
| BSPMDelisted Stock | USD 0.01 0.00 0.00% |
Biostar Pharmaceuticals fundamentals help investors to digest information that contributes to Biostar Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Biostar Pink Sheet. The fundamental analysis module provides a way to measure Biostar Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biostar Pharmaceuticals pink sheet.
Biostar |
Biostar Pharmaceuticals Company Price To Earning Analysis
Biostar Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Biostar Pharmaceuticals has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Pharmaceuticals, Biotechnology & Life Sciences (which currently averages 0.0) industry. The price to earning for all United States stocks is 100.0% higher than that of the company.
Biostar Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biostar Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Biostar Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Biostar Pharmaceuticals by comparing valuation metrics of similar companies.Biostar Pharmaceuticals is currently under evaluation in price to earning category among its peers.
Biostar Fundamentals
| Return On Equity | 0.0266 | ||||
| Return On Asset | 0.0425 | ||||
| Profit Margin | 2.94 % | ||||
| Operating Margin | 8.76 % | ||||
| Current Valuation | 316.46 K | ||||
| Shares Outstanding | 2.64 M | ||||
| Number Of Shares Shorted | 170.44 K | ||||
| Price To Book | 0.01 X | ||||
| Price To Sales | 0.0001 X | ||||
| Revenue | 317.79 K | ||||
| Gross Profit | 915.17 K | ||||
| EBITDA | (1.7 M) | ||||
| Net Income | (5.7 M) | ||||
| Cash And Equivalents | 364.97 K | ||||
| Cash Per Share | 0.14 X | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 0.19 X | ||||
| Book Value Per Share | 13.71 X | ||||
| Cash Flow From Operations | 4.91 M | ||||
| Short Ratio | 3.00 X | ||||
| Earnings Per Share | 0.06 X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 200 | ||||
| Beta | -2923.36 | ||||
| Market Capitalization | 94 | ||||
| Total Asset | 42.5 M | ||||
| Retained Earnings | 3.16 M | ||||
| Working Capital | 9.07 M | ||||
| Current Asset | 16.17 M | ||||
| Current Liabilities | 7.1 M | ||||
| Net Asset | 42.5 M |
About Biostar Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biostar Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biostar Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biostar Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Biostar Pink Sheet
If you are still planning to invest in Biostar Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostar Pharmaceuticals' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |